Abatacept in ANCA Associated Vasculitis

ANCA-associated Vasculitis Clinical Trial

— ABAVAS  

Official title:

A Pilot Study Examining the Effect of Abatacept in ANCA Associated Vasculitis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00482066
• Other study ID #: cro632
• Secondary ID: 2006-001859-35BM
• Status: Terminated
• Phase: Phase 2
• First received: June 1, 2007
• Last updated: May 28, 2015
• Start date: November 2007
• Est. completion date: November 2008

Study information

• Verified date: March 2015
• Source: Imperial College London
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate whether abatacept can prevent relapse in patients with ANCA associated vasculitis(AAV). This is a randomised double blinded placebo controlled trial.

Description:

The drugs that are normally used to treat patients with AAV are quite effective, but up to 20% of patients relapse within 18 months. The drugs used can also have significant side effects. Abatacept, also known as CTLA4Ig, acts by blocking vital costimulatory signals required for T lymphocytes to be activated. As ANCA associated vasculitis is believed to be an autoimmune condition and dependent on autoreactive T cells, there is some reason to believe this drug would be effective. Abatacept has already received a license by the FDA for use in Rheumatoid arthritis where it has proven to be effective even in patients unresponsive to Etanercept (TNF blockade).

120 patients with AAV will be invited to take part in this study, from hospitals in the UK and Europe. The patients will receive standard therapy with methotrexate and steroids as well as 12 months of abatacept or placebo. They will be followed for a further 12 months.

The primary objective of this study is to assess the relapse rate over 24 months, in patients with acute AAV, presenting at first diagnosis or relapse, in the two arms of the study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 7
• Est. completion date: November 2008
• Est. primary completion date: November 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Acute AAV, presenting at first diagnosis or relapse, defined by clinical presentation

• ANCA positivity (anti-MPO or anti-PR3 positive)

• BVAS score of > 8.

Exclusion Criteria:

• Severe life-threatening disease, i.e. lung haemorrhage at the time of presentation, renal impairment with SCr>150 micromol/l, or severe CNS dysfunction thought to be due to vasculitis.

• Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological or cerebral disease, or other medical conditions that might place the subject at unacceptable risk for participation in this study.

• Any other non-vasculitic multisystem autoimmune disease

• Serious acute or bacterial infection unless treated and completely resolved with antibiotics prior to enrolment

• With any severe chronic or recurrent bacterial infection

• With Hepatitis B or C or HIV

• With Herpes zoster infection that resolved less than 2 months prior to enrolment

• Subjects who have received any live vaccines within 3 months of the first dose of study medication or who will have need of a live vaccine at any time in the year following enrolment

• Subjects with current clinical or laboratory evidence of active or latent tuberculosis (TB) and subjects with a history of active TB treated within the last 3 years

• With any previous malignancy, with the exception of non-melanoma skin malignancies, adequately treated previously

• Subjects with a mammogram that is suspicious for malignancy and in whom the possibility of malignancy cannot be reasonably excluded following additional evaluations. Mammograms (females only) must be performed within 6 months of study entry or if documentation is not on file.

• With MTX treatment in prior 3 months

• Subjects with prior therapy with rituximab, anti-TNF therapy, or IL-1 receptor antagonists within last year or cyclophosphamide within last six months

• Subjects with a history of intolerance to methotrexate

• Subjects who have at any time received treatment with abatacept

• Subjects who have received treatment with any investigational drug within 28 days (or less than 5 terminal half-lives of elimination) of the Day 1 dose

• Subject receiving approved or investigational biologics

• Subjects with any of the following laboratory values:

• Hgb < 8.5 g/dL.

• WBC < 3,000/mm3 (3 x 109/L)

• Platelets < 100,000/mm3 (100 x 109/L).

• Serum ALT or AST > 2 times upper limit of normal.

• Any other laboratory test results that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study.

• Subjects participating concurrently in another clinical trial

• Pregnancy, breast feeding or inadequate contraception if female.

• Allergy to a study medication

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• ANCA-associated Vasculitis
• Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
• Vasculitis

Intervention

Drug:
• Abatacept (Orencia)
500mg for patients under 60kg 750mg for patients 60-100kg 1g for patients>100kg given as i.v. infusion over 30 minutes at day 0, 14, 28 and then monthly for a further 11 months 914 infusions in total) placebo groups receive saline only I.v.

Locations

Country	Name	City	State
United Kingdom	Imperial College London, Hammersmith Hospital	London

Sponsors (2)

Lead Sponsor	Collaborator
Imperial College London	Bristol-Myers Squibb

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relapse rate over 24 months.		2 years	Yes
Secondary	Proportion of patients in sustained remission (i.e. remission at 3 months sustained for 6 months and remission at 6 months sustained for a further 12 months);		2 years	Yes
Secondary	Time to remission;		2 years	Yes
Secondary	The average steroid dosage at 6 months, 1 year, 18 months and 2 years in abatacept and placebo groups respectively;		2 years	No
Secondary	Time to ANCA negativity by immunofluorescence or negative anti-PR3 or anti-MPO Ab test by ELISA.		2 years	No
Secondary	Proportion of patients defaulting to cyclophosphamide (MMF, azathioprine or other rescue) therapy.		2 years	Yes
Secondary	Proportion of patients unable to stick with trial protocol.		2 years	No
Secondary	Degree of chronic disease activity		2 years	Yes
Secondary	Health related quality of life		2 years	Yes